Re: [NMusers] Combined residual model and IWRES.

2008-02-14 Thread varun goel
)^2 ## = 0.51955 err.1-7.04 rse.err.1-54.4#% var.err.1-(rse.err.1*err.1/100)^2 ## = 14.66 ##now from delta method E(err)=2.65^2 ## 7.025 close to 7.04 var(err)=(2*2.65)^2*0.51955 ## 14.59 close to 14.66 Hope it helps Varun Goel PhD Candidate, Pharmacometrics Experimental

Re: [NMusers] Log Transformation in NONMEM

2008-06-16 Thread varun goel
Dear Mohamed, A logit transformation of data will transform your VAS scores from - infinity to + infinity. Varun Goel --- On Mon, 6/16/08, [EMAIL PROTECTED] lt;[EMAIL PROTECTED]gt; wrote: From: [EMAIL PROTECTED] lt;[EMAIL PROTECTED]gt; Subject: [NMusers] Log Transformation in NONMEM

Re: [NMusers] Error with SAEM and LIKE Option

2017-01-13 Thread varun goel
Hi Varun,   You might try explicitly using “NOINTERACTION” with SAEM and IMP.   Cheers… Brian   From: owner-nmus...@globomaxnm.com [mailto:owner-nmus...@globomaxnm.com]On Behalf Of varun goel Sent: Friday, January 13, 2017 9:55 AM To: nmusers@globomaxnm.com Subject: [NMusers] Error with SAEM

[NMusers] Error with SAEM and LIKE Option

2017-01-13 Thread varun goel
Dear All, I get error while using SAEM estimation method for repeated time to event model. But, the same model runs well with LAPLACE. Could you suggest what I am missing below.  This $EST runs well$ESTIMATION MAXEVAL=999 METHOD=COND LAPLACE LIKE PRINT=1 Following $EST method fails with the

[NMusers] Summer Internships on Application of RNAi PKPD at Alnylam; Cambridge, MA

2017-04-20 Thread varun goel
Summer Internship Alnylam was founded in 2002 on a revolutionaryvision and bold mission which remain firmly in place today. We are leading thetranslation of RNAi as a new class of medicines with a core focus on RNAitherapeutics toward genetically defined targets for the treatment of

[NMusers] Summer internship: PKPD of siRNA therapeutics, Alnylam, Cambridge, MA

2018-03-22 Thread varun goel
Company Overview Alnylam was founded in 2002 on a revolutionary vision and bold mission which remain firmly in place today. We are leading the translation of RNAi as a new class of medicines with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious,